Amarantus Bioscience Holdings Inc (AMBS)

[MagicCap]

The 1/8/13 conference will be a major catalyst. Having the founder of a $67 billion company presenting on your behalf about the commercial opportunities of your drug should add just a teeny weeny amount of credibility.

Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?

MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.

http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s

AMBS is only worth $24 Million right now.

Versus $250 Million.

Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.

In their own words:

"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."

I'm putting my money with the co-founder of Amgen, not some college kids on this board with $3,000 who are naive enough to think they have any power over a stock.